TO ASSESS THE RELIEF OF SYMPTOMS LIKE BLOOD LOSS,ABDOMINAL PAIN AND ASSOCIATED SYMPTOMS IN PATIENTS DIAGNOSED WITH ADENOMYOSIS AFTER USING THE DRUG ORMELOXIFENE FOR 6 MONTHS

Phase 2

• Conditions: Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

• Registration Number: CTRI/2023/12/060676
• Lead Sponsor: Jawaharlal Institute of Postgraduate Medical Education and Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1)Patients with adenomyosis with heavy menstrual bleeding and/or dysmenorrhea, dyspareunia

2)women > 25 years who have completed family

Exclusion Criteria

1)Associated pelvic pathology like fibroid, endometriosis, malignancy

2)contra indications to Ormeloxifene like PCOS, renal impairment, liver impairment, recent h/o jaundice, pregnancy, lactation, hypersensitivity

3)chronic pelvic pain

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess menstrual flow volume, dysmenorrhea, <br/ ><br>and quality of life after 3 and 6 months of using OrmeloxifeneTimepoint: 0,3,6 months

Secondary Outcome Measures

Name	Time	Method
To assess side effects of the drug and failure rates.Timepoint: 0,3,6 months